Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for gut inflammation in HIV
NCT05362916Completed
- Start
- Sep 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of letermovir in human immunodeficiency virus infection (HIV). Started Sep 2022; status: completed.
02
Drugs
letermovir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05362916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362916.